Physician profile
Wasan Cartwright
NPI 1073123063
$4,375.73
in general payments reported to CMS, 2019-2025
21 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.55 · 2022: $59.25 · 2023: $1,002 · 2024: $1,405 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.93 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $996.25 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $489.96 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $476.04 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $355.56 | 2023-2025 | Xolair |
| Csl Behring | $311.88 | 2023-2025 | Hizentra, Privigen |
| Grifols USA, LLC | $244.23 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Incyte Corporation | $239.78 | 2023-2025 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $221.70 | 2023-2025 | Cuvitru, Hyqvia, Eohilia |
| Novartis Pharmaceuticals Corporation | $199.97 | 2024-2025 | |
| Amgen INC. | $169.30 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $161.48 | 2023-2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $129.41 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $99.18 | 2023-2025 | Orladeyo |
| Aerin Medical INC. | $51.65 | 2024-2025 | |
| Indivior INC. | $49.88 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $48.92 | 2021-2022 | |
| Blueprint Medicines Corporation | $45.74 | 2023 | Ayvakit |
| Biogen, INC. | $24.87 | 2023 | Spinraza |
| Viatris Specialty LLC | $21.12 | 2025 | Yupelri |
| Leo Pharma INC. | $19.66 | 2025 | Anzupgo |
| Lilly USA, LLC | $19.15 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasan Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.